Developer docs
API playgroundTry for free, no card

Search company profiles

Harvard Stem Cell Institute

Full company profile

uuid003gqet

Namestring
Harvard Stem Cell Institute
Legal namestring
Harvard Stem Cell Institute
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Harvard Stem Cell Institute (HSCI) is a University-wide interfaculty initiative within Harvard University, founded in 2004 by Doug Melton and David Scadden to advance stem cell and regenerative biology toward clinical application. It operates as a network of more than 350 research faculty and their labs distributed across Harvard's schools, centers, eight affiliated teaching hospitals, and partner companies in Cambridge and Boston, organized around nine disease programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Musculoskeletal, Nervous System Diseases, Skin, and Aging & Fibrosis). The institute also provides shared core facilities including the iPS Core Facility, the Center for Stem Cell Bioinformatics, and the Center for Human Cell Therapy, plus training programs such as the HSCI Internship Program and MD/PhD Fellowships.

HSCI's core technology stack spans induced pluripotent stem (iPS) cell derivation, CRISPR-Cas9 and related gene editing, organoid culture systems, and bioengineered tissue platforms for disease modeling and therapeutic development. The institute seeds high-risk/high-reward research through Capstone Grants (~$250K/investigator/year for 3-5 years), Seed Grants ($50K/year for up to two years), and the Barry Family HSCI Innovation Award ($250K annually), with a third of its grants reportedly attracting follow-on funding at approximately three times the original investment.

HSCI is a non-profit academic research institute and does not sell commercial products. Its revenue model rests on philanthropic giving, foundation grants, NIH funding, fee-for-service work at the iPS Core Facility, and technology licensing and startup formation. Discoveries are translated through licensing deals (e.g., Vertex Pharmaceuticals licensing the Melton Lab beta cell technology for VX-880), industry collaborations (Bristol-Myers Squibb, Boehringer Ingelheim, Frequency Therapeutics), and a startup ecosystem of 50+ faculty-founded companies including Moderna Therapeutics, CRISPR Therapeutics, Semma Therapeutics (acquired by Vertex in 2019), Fate Therapeutics, Sana Biotechnology, Garuda Therapeutics, and Elevian. Leadership transitioned in spring 2026 with Lee Rubin appointed as co-director alongside David Scadden, succeeding co-founder Doug Melton.

Short descriptiontext

Harvard Stem Cell Institute is a Harvard University research initiative advancing stem cell and regenerative biology across 350+ faculty, nine disease programs, and shared core facilities, funding early-stage research and translating discoveries into clinical applications through licensing and a startup ecosystem.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell research, regenerative medicine, translational research, biomedical research funding, research training programs
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYEDAHABAB
STEM-Focused Research Universities (Engineering & Applied Sciences)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biomedical Research - Stem Cell and Regenerative Medicine
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Philanthropic Gifts and Grants
TypeLicensing Royalties
Description

HSCI depends on sustained support from individuals, foundations, and company leaders. Philanthropic gifts are leveraged to attract NIH and other larger funding sources. A third of grants attract further funding at approximately 3x HSCI's original investment.

hsci.harvard.edu
2Technology Licensing and Startup Revenue
TypeLicensing Royalties
Description

Discoveries from collaborative projects are often licensed, enabling venture capitalists and industry to invest. Startup companies develop foundational discoveries into new therapeutic products and platforms, creating potential licensing and royalty streams.

hsci.harvard.edu
3Fee-for-Service Core Facilities
TypeProfessional Services
Description

The iPS Core Facility operates on a fee-for-service business model providing investigators with customized iPS derivation and genome editing services.

hsci.harvard.edu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Harvard Stem Cell Institute operates as a University-wide research initiative that conducts stem cell and regenerative biology research, provides shared core facilities (iPS derivation, gene editing, bioinformatics), funds early-stage research through seed and capstone grants, supports faculty startup formation, and runs training programs including internships and fellowships. Its primary mission is to translate stem cell discoveries into clinical treatments for diseases including diabetes, cancer, cardiovascular disease, and neurodegenerative conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Vertex Pharmaceuticals' VX-880 (based on Melton Lab/HSCI research) achieved promising early results as an investigational stem cell-derived islet cell replacement therapy for Type 1 diabetes.
+3 more records
Product overview1 text field

Harvard Stem Cell Institute (HSCI) is a university-wide research initiative that functions as a collaborative platform rather than a commercial product company. The organization operates multiple interconnected research programs including disease-specific programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Nervous System Diseases, Musculoskeletal, Skin), early-stage research funding mechanisms (Seed Grants, Capstone Grants, Barry Family Innovation Award), training programs (HIP Internship, MD/PhD Fellowship), and shared core facilities (iPS Core, Center for Stem Cell Bioinformatics, Center for Human Cell Therapy). These components work together to advance stem cell biology and translate discoveries into clinical applications for patients.

Product and service18 records
1HSCI iPS Core Facility
CategoryCore Research Facility
Description

A fee-for-service facility providing customized induced pluripotent stem (iPS) cell derivation and genome editing based on cutting-edge stem cell technologies to accelerate research in the stem cell field. Used by investigators across Harvard and partner institutions.

2HSCI Center for Stem Cell Bioinformatics (CSCB)
CategoryCore Research Facility
Description

A center providing training, consulting services, and the Stem Cell Commons collaborative data repository and analysis platform for managing high-throughput sequencing data in stem cell research.

3Center for Human Cell Therapy (CHCT)/TransLab
CategoryCore Research Facility
Description

A scientific and technical platform at Boston Children's Hospital dedicated to supporting clinical research and bench-to-bedside development of cellular therapies, providing services including cellular assays, immunophenotyping, RNA/DNA molecular assays, and FDA-compliant cell-based therapy process development.

4HSCI Internship Program (HIP)
CategoryTraining Program
Description

A 9-week summer research internship program providing undergraduate students with focused, hands-on research experience in cutting-edge stem cell science laboratories, including a stem cell seminar series and career pathways presentation. Housing and meal plans provided at no cost to selected interns.

5MD/PhD Training Fellowship
CategoryTraining Program
Description

A medical scientist training fellowship awarded to Harvard Medical School students demonstrating strong interest in stem cell research, supporting their development as physician-scientists.

6Capstone Grants
CategoryResearch Funding Program
Description

3-5 year RO1-level grants of approximately $250,000 per investigator per year for capstone projects incorporating evolving technologies to resolve issues in regenerative biology with clear line of sight to human application.

7Seed Grants
CategoryResearch Funding Program
Description

Early-stage funding of $50,000 per year for up to two years for innovative projects in stem cell and regenerative biology that support bold thinking and launch scientific careers.

8Barry Family HSCI Innovation Award
CategoryResearch Funding Program
Description

Annual $250,000 award for early career investigators to explore basic biology and translational potential of stem cell-based science with potential to transform the field.

9Blood Diseases Program
CategoryDisease Research Program
Description

Disease-specific research program investigating how blood stem cells manage self-renewal, with implications for leukemia, lymphoma, and regenerative medicine.

10Cancer Program
CategoryDisease Research Program
Description

Disease-specific research program working to develop therapies that can eradicate cancer cells without harming healthy tissues by understanding how normal stem cells become cancer cells.

11Cardiovascular Disease Program
CategoryDisease Research Program
Description

Disease-specific research program aimed at generating new human heart cells to replace damaged heart tissue, developing approaches to harness regeneration for therapy.

12Diabetes Program
CategoryDisease Research Program
Description

Disease-specific research program focused on curing diabetes by creating insulin-producing beta cells and protecting them from immune system attack for transplantation.

13Kidney Disease Program
CategoryDisease Research Program
Description

Disease-specific research program dedicated to finding new treatments for patients with kidney disease, focusing on nephron biology and regeneration.

14Nervous System Diseases Program
CategoryDisease Research Program
Description

Disease-specific research program investigating neurodegenerative and traumatic diseases of the brain and spinal cord, covering ALS, Alzheimer's, eye diseases, hearing loss, Multiple Sclerosis, and Parkinson's.

15Musculoskeletal Program
CategoryDisease Research Program
Description

Disease-specific research program applying stem cell and developmental biology discoveries to develop innovative solutions for musculoskeletal injury and disease using regenerative medicine approaches.

16Skin Program
CategoryDisease Research Program
Description

Disease-specific research program using stem cells to regenerate tissue without scarring, exploring fundamental roles of skin stem cells in regenerative wound healing, cancers, and skin aging.

17Stem Cells as Tools Research Platform
CategoryResearch Platform
Description

Research platform using stem cells to study human disease in dishes at multiple levels: individual cells, multiple cell types, tissues (organoids), and bioengineered tissues, combined with gene editing capabilities.

18Harvard Fibrosis Network
CategoryResearch Collaboration Network
Description

Cross-disciplinary network partnering with pharmaceutical companies (Bristol-Myers Squibb, Boehringer Ingelheim) to study fibrosis across kidney, lung, heart, liver, and other organs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership23 partners
1Garuda Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Founded by former Principal Faculty member Dhvanit Shah in 2021, Garuda Therapeutics developed a platform for generating off-the-shelf, self-renewing blood stem cells. HSCI Co-Director David Scadden is a co-founder and Scientific Advisory Board member.

hsci.harvard.edu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Sana Biotechnology, co-founded by HSCI Principal Faculty member Chad Cowan in 2019, is focused on creating and delivering engineered cells as medicine for patients, representing HSCI technology moving into commercial development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Co-founded by HSCI Affiliate Faculty member Luk Vandenberghe in 2019, Affinia Therapeutics develops a platform for rationally designed AAV vectors and gene therapies for muscle and CNS diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

HSCI Affiliate Faculty member Luk Vandenberghe co-founded Akouos in 2017, a biotechnology company developing gene therapies for hearing loss.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

HSCI Principal Faculty member Jeffrey Karp is a co-founder and Scientific Advisory Board member of Alivio Therapeutics, developing novel drug delivery technology for inflammatory disease treatment.

6Bristol-Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bristol-Myers Squibb is a partner in the Harvard Fibrosis Network, an HSCI-led initiative that looks for commonalities across fibrotic diseases, sharing expertise in kidney, lung, heart, liver, and other organ fibrosis. The collaboration brings academic, clinical, and pharmaceutical research practice together to advance fibrosis treatments.

hsci.harvard.edu
7Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Boehringer Ingelheim participates in the Harvard Fibrosis Network, collaborating with HSCI scientists on studies of fibrosis of the kidney, lung, heart, liver, and other organs, combining academic and pharmaceutical research approaches.

hsci.harvard.edu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI scientists are collaborating with Frequency Therapeutics and the U.S. Army Institute of Surgical Research using small-molecule drugs to address different muscle conditions. HSCI Principal Faculty member Jeffrey Karp is a co-founder of Frequency Therapeutics.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

A three-way collaboration between the U.S. Army Institute of Surgical Research, Harvard University, and Frequency Therapeutics, using small-molecule drugs to address different muscle conditions, with HSCI scientists providing stem cell research expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for Type 1 diabetes, utilizing research from the Melton Lab at HSCI. This represents a major translation of HSCI discoveries into clinical application.

11Boston Autologous Islet Replacement Program (BAIRT)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BAIRT is a unique collaboration involving HSCI, Brigham and Women's Hospital, the Joslin Diabetes Center, and the Dana-Farber Cancer Institute, working together to generate clinical-grade, pluripotent stem cells suitable for use in patients to advance beta cell replacement therapy for diabetes.

hsci.harvard.edu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI is an integral member of the JDRF New England Center of Excellence, a cross-institutional collaboration with Joslin Diabetes Center, UMass Chan Medical School, Dana-Farber Cancer Institute, and the Jackson Laboratory, working toward engineering beta cells to enable transplantation without immunosuppression.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI Principal Faculty member Chad Cowan is a scientific co-founder of CRISPR Therapeutics, a biopharmaceutical company created to translate CRISPR-Cas9 genome-editing technology into transformative medicines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI Principal Faculty member Derrick Rossi translated a discovery from his laboratory into mRNA-based therapeutics, co-founding Moderna Therapeutics, which uses messenger RNA to produce human proteins inside patient cells.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Semma Therapeutics was founded by HSCI Co-Director Douglas Melton to develop transformative therapies for patients who depend on insulin injections, leveraging breakthroughs from his laboratory. Semma was acquired by Vertex Pharmaceuticals in 2019.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI Co-Director David Scadden and Principal Faculty member Derrick Rossi are scientific co-founders of Magenta Therapeutics, focused on improving the patient experience in transplant medicine and making bone marrow transplantation accessible to more patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI Co-Director David Scadden and Executive Committee Chair Leonard Zon are co-founders of Fate Therapeutics, focused on adult stem cell modulators for rare, life-threatening disorders including hematologic malignancies and muscular dystrophies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded by HSCI Principal Faculty members Richard Lee, Lee Rubin, and Amy Wagers, Elevian is developing regenerative medicines targeting processes that are the root causes of aging.

19Goldfinch Bio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

HSCI Executive Committee member Joseph Bonventre is a scientific co-founder of Goldfinch Bio, focused on discovering and developing precision therapies for patients with kidney disease.

hsci.harvard.edu
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Founded by HSCI Faculty Kevin Eggan, Kasper Roet, and Clifford Woolf, QurAlis is focused on discovering and developing new therapies for ALS, the most common form of motor neuron disease.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Keros is a clinical-stage biopharmaceutical company focused on treatments for rare blood and musculoskeletal disorders, with HSCI Affiliate Faculty member Paul Yu as scientific founder and HSCI Executive Committee member Vicki Rosen on the Scientific Advisory Board.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSCI Co-Director Douglas Melton, along with Principal Faculty members George Daley and Lee Rubin, co-founded iPierian in 2007 to develop therapies for Alzheimer's and neurodegenerative diseases. Acquired by Bristol-Myers Squibb in 2014.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

HSCI Principal Faculty member Harald Ott is founder and Chairman of the Board of IVIVA Medical, developing tissue-engineered treatments for end-stage renal disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Stanford Institute for Stem Cell Biology and Regenerative Medicine
TypeDirect peer
Description

Stanford's flagship stem cell research institute brings together faculty across Stanford schools and hospitals to advance regenerative medicine. It is the closest direct peer to HSCI in terms of scope, prestige, and cross-institutional model.

TypeBroad incumbent
Description

Scripps Research is a large non-profit biomedical research organization conducting wide-ranging research including regenerative medicine and stem cell biology. It is a broader biomedical research institution with overlapping stem cell science programs.

TypeRegional player
Description

The Wellcome Sanger Institute is a leading UK-based genomic and cellular research institute with significant stem cell biology and organoid research programs (e.g., Human Cell Atlas). It is comparable to HSCI in terms of scientific scope but operates in a different geography.

TypeDirect peer
Description

The Whitehead Institute is a leading non-profit biomedical research institute affiliated with MIT that conducts research in regenerative biology, stem cells, and disease mechanisms. It is a comparable elite-tier research organization focused on fundamental biology with translational potential.

TypeBroad incumbent
Description

The Broad Institute is a major biomedical research institution affiliated with both MIT and Harvard that conducts large-scale genomic and disease research. While broader in scope than HSCI, it shares faculty with Harvard and overlapping stem cell and regenerative biology research programs.

TypeDirect peer
Description

The Buck Institute is California's first biomedical research institute focused on aging and age-related diseases, with significant stem cell and regenerative biology research. It shares HSCI's focus on aging-related disease research and translational stem cell science.

TypeDirect peer
Description

The Allen Institute for Cell Science is a Seattle-based research institute focused on understanding cell behavior and fate using stem cell-derived models, including organoids and gene editing. It shares HSCI's emphasis on stem cell-derived platforms and tools for disease research.

TypeDirect peer
Description

Gladstone Institutes is a San Francisco-based independent biomedical research organization affiliated with UCSF that focuses on regenerative medicine, stem cell biology, and disease-focused research. It has a similar disease-program structure and translational orientation to HSCI.

TypeDirect peer
Description

This center at Cincinnati Children's Hospital is a leading pediatric stem cell research hub focused on organoid biology and regenerative medicine. It shares HSCI's emphasis on organoid technology and disease modeling.

TypeDirect peer
Description

NYSCF is a leading non-profit research organization focused on stem cell research and translational applications. It operates a research institute and works across multiple disease areas similar to HSCI, though without the embedded university network model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Harvard Stem Cell Institute

Biomedical Research - Stem Cell and Regenerative Medicinehsci.harvard.edu

Harvard Stem Cell Institute is a Harvard University research initiative advancing stem cell and regenerative biology across 350+ faculty, nine disease programs, and shared core facilities, funding early-stage research and translating discoveries into clinical applications through licensing and a startup ecosystem.

What Harvard Stem Cell Institute does

Harvard Stem Cell Institute (HSCI) is a University-wide interfaculty initiative within Harvard University, founded in 2004 by Doug Melton and David Scadden to advance stem cell and regenerative biology toward clinical application. It operates as a network of more than 350 research faculty and their labs distributed across Harvard's schools, centers, eight affiliated teaching hospitals, and partner companies in Cambridge and Boston, organized around nine disease programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Musculoskeletal, Nervous System Diseases, Skin, and Aging & Fibrosis). The institute also provides shared core facilities including the iPS Core Facility, the Center for Stem Cell Bioinformatics, and the Center for Human Cell Therapy, plus training programs such as the HSCI Internship Program and MD/PhD Fellowships.

HSCI's core technology stack spans induced pluripotent stem (iPS) cell derivation, CRISPR-Cas9 and related gene editing, organoid culture systems, and bioengineered tissue platforms for disease modeling and therapeutic development. The institute seeds high-risk/high-reward research through Capstone Grants (~$250K/investigator/year for 3-5 years), Seed Grants ($50K/year for up to two years), and the Barry Family HSCI Innovation Award ($250K annually), with a third of its grants reportedly attracting follow-on funding at approximately three times the original investment.

HSCI is a non-profit academic research institute and does not sell commercial products. Its revenue model rests on philanthropic giving, foundation grants, NIH funding, fee-for-service work at the iPS Core Facility, and technology licensing and startup formation. Discoveries are translated through licensing deals (e.g., Vertex Pharmaceuticals licensing the Melton Lab beta cell technology for VX-880), industry collaborations (Bristol-Myers Squibb, Boehringer Ingelheim, Frequency Therapeutics), and a startup ecosystem of 50+ faculty-founded companies including Moderna Therapeutics, CRISPR Therapeutics, Semma Therapeutics (acquired by Vertex in 2019), Fate Therapeutics, Sana Biotechnology, Garuda Therapeutics, and Elevian. Leadership transitioned in spring 2026 with Lee Rubin appointed as co-director alongside David Scadden, succeeding co-founder Doug Melton.

Harvard Stem Cell Institute firmographics

Firmographics
Name
Harvard Stem Cell Institute
Legal name
Harvard Stem Cell Institute
Website
https://hsci.harvard.edu
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
Harvard Stem Cell Institute is a Harvard University research initiative advancing stem cell and regenerative biology across 350+ faculty, nine disease programs, and shared core facilities, funding early-stage research and translating discoveries into clinical applications through licensing and a startup ecosystem.
Ownership category
akta.pro rank

Harvard Stem Cell Institute industry classification

Industry
Product category
Biomedical Research - Stem Cell and Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYEDAHABAB
STEM-Focused Research Universities (Engineering & Applied Sciences)

Keywords

  • Stem cell research
  • Regenerative medicine
  • Translational research
  • Biomedical research funding
  • Research training programs

Where Harvard Stem Cell Institute is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Harvard Stem Cell Institute business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Philanthropic Gifts and Grants: HSCI depends on sustained support from individuals, foundations, and company leaders. Philanthropic gifts are leveraged to attract NIH and other larger funding sources. A third of grants attract further funding at approximately 3x HSCI's original investment.
  2. Technology Licensing and Startup Revenue: Discoveries from collaborative projects are often licensed, enabling venture capitalists and industry to invest. Startup companies develop foundational discoveries into new therapeutic products and platforms, creating potential licensing and royalty streams.
  3. Fee-for-Service Core Facilities: The iPS Core Facility operates on a fee-for-service business model providing investigators with customized iPS derivation and genome editing services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Harvard Stem Cell Institute product offering

Product offering

Core offering

Harvard Stem Cell Institute operates as a University-wide research initiative that conducts stem cell and regenerative biology research, provides shared core facilities (iPS derivation, gene editing, bioinformatics), funds early-stage research through seed and capstone grants, supports faculty startup formation, and runs training programs including internships and fellowships. Its primary mission is to translate stem cell discoveries into clinical treatments for diseases including diabetes, cancer, cardiovascular disease, and neurodegenerative conditions.

Product overview

Harvard Stem Cell Institute (HSCI) is a university-wide research initiative that functions as a collaborative platform rather than a commercial product company. The organization operates multiple interconnected research programs including disease-specific programs (Blood, Cancer, Cardiovascular, Diabetes, Kidney, Nervous System Diseases, Musculoskeletal, Skin), early-stage research funding mechanisms (Seed Grants, Capstone Grants, Barry Family Innovation Award), training programs (HIP Internship, MD/PhD Fellowship), and shared core facilities (iPS Core, Center for Stem Cell Bioinformatics, Center for Human Cell Therapy). These components work together to advance stem cell biology and translate discoveries into clinical applications for patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • HSCI iPS Core Facility A fee-for-service facility providing customized induced pluripotent stem (iPS) cell derivation and genome editing based on cutting-edge stem cell technologies to accelerate research in the stem cell field. Used by investigators across Harvard and partner institutions.
  • HSCI Center for Stem Cell Bioinformatics (CSCB) A center providing training, consulting services, and the Stem Cell Commons collaborative data repository and analysis platform for managing high-throughput sequencing data in stem cell research.
  • Center for Human Cell Therapy (CHCT)/TransLab A scientific and technical platform at Boston Children's Hospital dedicated to supporting clinical research and bench-to-bedside development of cellular therapies, providing services including cellular assays, immunophenotyping, RNA/DNA molecular assays, and FDA-compliant cell-based therapy process development.
  • HSCI Internship Program (HIP) A 9-week summer research internship program providing undergraduate students with focused, hands-on research experience in cutting-edge stem cell science laboratories, including a stem cell seminar series and career pathways presentation. Housing and meal plans provided at no cost to selected interns.
  • MD/PhD Training Fellowship A medical scientist training fellowship awarded to Harvard Medical School students demonstrating strong interest in stem cell research, supporting their development as physician-scientists.
  • Capstone Grants 3-5 year RO1-level grants of approximately $250,000 per investigator per year for capstone projects incorporating evolving technologies to resolve issues in regenerative biology with clear line of sight to human application.
  • Seed Grants Early-stage funding of $50,000 per year for up to two years for innovative projects in stem cell and regenerative biology that support bold thinking and launch scientific careers.
  • Barry Family HSCI Innovation Award Annual $250,000 award for early career investigators to explore basic biology and translational potential of stem cell-based science with potential to transform the field.
  • Blood Diseases Program Disease-specific research program investigating how blood stem cells manage self-renewal, with implications for leukemia, lymphoma, and regenerative medicine.
  • Cancer Program Disease-specific research program working to develop therapies that can eradicate cancer cells without harming healthy tissues by understanding how normal stem cells become cancer cells.
  • Cardiovascular Disease Program Disease-specific research program aimed at generating new human heart cells to replace damaged heart tissue, developing approaches to harness regeneration for therapy.
  • Diabetes Program Disease-specific research program focused on curing diabetes by creating insulin-producing beta cells and protecting them from immune system attack for transplantation.
  • Kidney Disease Program Disease-specific research program dedicated to finding new treatments for patients with kidney disease, focusing on nephron biology and regeneration.
  • Nervous System Diseases Program Disease-specific research program investigating neurodegenerative and traumatic diseases of the brain and spinal cord, covering ALS, Alzheimer's, eye diseases, hearing loss, Multiple Sclerosis, and Parkinson's.
  • Musculoskeletal Program Disease-specific research program applying stem cell and developmental biology discoveries to develop innovative solutions for musculoskeletal injury and disease using regenerative medicine approaches.
  • Skin Program Disease-specific research program using stem cells to regenerate tissue without scarring, exploring fundamental roles of skin stem cells in regenerative wound healing, cancers, and skin aging.
  • Stem Cells as Tools Research Platform Research platform using stem cells to study human disease in dishes at multiple levels: individual cells, multiple cell types, tissues (organoids), and bioengineered tissues, combined with gene editing capabilities.
  • Harvard Fibrosis Network Cross-disciplinary network partnering with pharmaceutical companies (Bristol-Myers Squibb, Boehringer Ingelheim) to study fibrosis across kidney, lung, heart, liver, and other organs.

Quantifiable outcome

  • Vertex Pharmaceuticals' VX-880 (based on Melton Lab/HSCI research) achieved promising early results as an investigational stem cell-derived islet cell replacement therapy for Type 1 diabetes.
  • +3 more outcomes

Companies that use Harvard Stem Cell Institute

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Harvard Stem Cell Institute technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Harvard Stem Cell Institute partnerships and signals

Strategic signal

Partnerships

23 partnerships are on record, tiered core and minor.

  • Garuda TherapeuticscoreStrategic or Co-development Partner · 1 January 2021Founded by former Principal Faculty member Dhvanit Shah in 2021, Garuda Therapeutics developed a platform for generating off-the-shelf, self-renewing blood stem cells. HSCI Co-Director David Scadden is a co-founder and Scientific Advisory Board member.
  • Sana BiotechnologycoreStrategic or Co-development Partner · 1 January 2019Sana Biotechnology, co-founded by HSCI Principal Faculty member Chad Cowan in 2019, is focused on creating and delivering engineered cells as medicine for patients, representing HSCI technology moving into commercial development.
  • Affinia TherapeuticscoreStrategic or Co-development Partner · 1 January 2019Co-founded by HSCI Affiliate Faculty member Luk Vandenberghe in 2019, Affinia Therapeutics develops a platform for rationally designed AAV vectors and gene therapies for muscle and CNS diseases.
  • AkouoscoreStrategic or Co-development Partner · 1 January 2017HSCI Affiliate Faculty member Luk Vandenberghe co-founded Akouos in 2017, a biotechnology company developing gene therapies for hearing loss.
  • Alivio TherapeuticsminorStrategic or Co-development Partner · 1 January 2016HSCI Principal Faculty member Jeffrey Karp is a co-founder and Scientific Advisory Board member of Alivio Therapeutics, developing novel drug delivery technology for inflammatory disease treatment.
  • Bristol-Myers SquibbcoreStrategic or Co-development PartnerBristol-Myers Squibb is a partner in the Harvard Fibrosis Network, an HSCI-led initiative that looks for commonalities across fibrotic diseases, sharing expertise in kidney, lung, heart, liver, and other organ fibrosis. The collaboration brings academic, clinical, and pharmaceutical research practice together to advance fibrosis treatments.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerBoehringer Ingelheim participates in the Harvard Fibrosis Network, collaborating with HSCI scientists on studies of fibrosis of the kidney, lung, heart, liver, and other organs, combining academic and pharmaceutical research approaches.
  • Frequency TherapeuticscoreStrategic or Co-development PartnerHSCI scientists are collaborating with Frequency Therapeutics and the U.S. Army Institute of Surgical Research using small-molecule drugs to address different muscle conditions. HSCI Principal Faculty member Jeffrey Karp is a co-founder of Frequency Therapeutics.
  • U.S. Army Institute of Surgical ResearchminorStrategic or Co-development PartnerA three-way collaboration between the U.S. Army Institute of Surgical Research, Harvard University, and Frequency Therapeutics, using small-molecule drugs to address different muscle conditions, with HSCI scientists providing stem cell research expertise.
  • Vertex PharmaceuticalscoreStrategic or Co-development PartnerVertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for Type 1 diabetes, utilizing research from the Melton Lab at HSCI. This represents a major translation of HSCI discoveries into clinical application.
  • Boston Autologous Islet Replacement Program (BAIRT)coreStrategic or Co-development PartnerBAIRT is a unique collaboration involving HSCI, Brigham and Women's Hospital, the Joslin Diabetes Center, and the Dana-Farber Cancer Institute, working together to generate clinical-grade, pluripotent stem cells suitable for use in patients to advance beta cell replacement therapy for diabetes.
  • JDRF New England Center of ExcellencecoreStrategic or Co-development PartnerHSCI is an integral member of the JDRF New England Center of Excellence, a cross-institutional collaboration with Joslin Diabetes Center, UMass Chan Medical School, Dana-Farber Cancer Institute, and the Jackson Laboratory, working toward engineering beta cells to enable transplantation without immunosuppression.
  • CRISPR TherapeuticscoreStrategic or Co-development PartnerHSCI Principal Faculty member Chad Cowan is a scientific co-founder of CRISPR Therapeutics, a biopharmaceutical company created to translate CRISPR-Cas9 genome-editing technology into transformative medicines.
  • Moderna TherapeuticscoreStrategic or Co-development PartnerHSCI Principal Faculty member Derrick Rossi translated a discovery from his laboratory into mRNA-based therapeutics, co-founding Moderna Therapeutics, which uses messenger RNA to produce human proteins inside patient cells.
  • Semma Therapeutics (acquired by Vertex 2019)coreStrategic or Co-development PartnerSemma Therapeutics was founded by HSCI Co-Director Douglas Melton to develop transformative therapies for patients who depend on insulin injections, leveraging breakthroughs from his laboratory. Semma was acquired by Vertex Pharmaceuticals in 2019.
  • Magenta TherapeuticscoreStrategic or Co-development PartnerHSCI Co-Director David Scadden and Principal Faculty member Derrick Rossi are scientific co-founders of Magenta Therapeutics, focused on improving the patient experience in transplant medicine and making bone marrow transplantation accessible to more patients.
  • Fate TherapeuticscoreStrategic or Co-development PartnerHSCI Co-Director David Scadden and Executive Committee Chair Leonard Zon are co-founders of Fate Therapeutics, focused on adult stem cell modulators for rare, life-threatening disorders including hematologic malignancies and muscular dystrophies.
  • EleviancoreStrategic or Co-development PartnerCo-founded by HSCI Principal Faculty members Richard Lee, Lee Rubin, and Amy Wagers, Elevian is developing regenerative medicines targeting processes that are the root causes of aging.
  • Goldfinch BiominorStrategic or Co-development PartnerHSCI Executive Committee member Joseph Bonventre is a scientific co-founder of Goldfinch Bio, focused on discovering and developing precision therapies for patients with kidney disease.
  • QurAlisminorStrategic or Co-development PartnerFounded by HSCI Faculty Kevin Eggan, Kasper Roet, and Clifford Woolf, QurAlis is focused on discovering and developing new therapies for ALS, the most common form of motor neuron disease.
  • Keros TherapeuticsminorStrategic or Co-development PartnerKeros is a clinical-stage biopharmaceutical company focused on treatments for rare blood and musculoskeletal disorders, with HSCI Affiliate Faculty member Paul Yu as scientific founder and HSCI Executive Committee member Vicki Rosen on the Scientific Advisory Board.
  • iPierian (Acquired by Bristol-Myers Squibb 2014)coreStrategic or Co-development PartnerHSCI Co-Director Douglas Melton, along with Principal Faculty members George Daley and Lee Rubin, co-founded iPierian in 2007 to develop therapies for Alzheimer's and neurodegenerative diseases. Acquired by Bristol-Myers Squibb in 2014.
  • IVIVA MedicalminorStrategic or Co-development PartnerHSCI Principal Faculty member Harald Ott is founder and Chairman of the Board of IVIVA Medical, developing tissue-engineered treatments for end-stage renal disease.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Harvard Stem Cell Institute competitors and assessment

Company assessment

Direct peers

  • Stanford Institute for Stem Cell Biology and Regenerative Medicine: Stanford's flagship stem cell research institute brings together faculty across Stanford schools and hospitals to advance regenerative medicine. It is the closest direct peer to HSCI in terms of scope, prestige, and cross-institutional model.
  • Whitehead Institute for Biomedical Research: The Whitehead Institute is a leading non-profit biomedical research institute affiliated with MIT that conducts research in regenerative biology, stem cells, and disease mechanisms. It is a comparable elite-tier research organization focused on fundamental biology with translational potential.
  • Buck Institute for Research on Aging: The Buck Institute is California's first biomedical research institute focused on aging and age-related diseases, with significant stem cell and regenerative biology research. It shares HSCI's focus on aging-related disease research and translational stem cell science.
  • Allen Institute for Cell Science: The Allen Institute for Cell Science is a Seattle-based research institute focused on understanding cell behavior and fate using stem cell-derived models, including organoids and gene editing. It shares HSCI's emphasis on stem cell-derived platforms and tools for disease research.
  • Gladstone Institutes: Gladstone Institutes is a San Francisco-based independent biomedical research organization affiliated with UCSF that focuses on regenerative medicine, stem cell biology, and disease-focused research. It has a similar disease-program structure and translational orientation to HSCI.
  • Cincinnati Children's Center for Stem Cell and Organoid Medicine: This center at Cincinnati Children's Hospital is a leading pediatric stem cell research hub focused on organoid biology and regenerative medicine. It shares HSCI's emphasis on organoid technology and disease modeling.
  • New York Stem Cell Foundation (NYSCF): NYSCF is a leading non-profit research organization focused on stem cell research and translational applications. It operates a research institute and works across multiple disease areas similar to HSCI, though without the embedded university network model.

Broad incumbents

  • Scripps Research Institute: Scripps Research is a large non-profit biomedical research organization conducting wide-ranging research including regenerative medicine and stem cell biology. It is a broader biomedical research institution with overlapping stem cell science programs.
  • Broad Institute of MIT and Harvard: The Broad Institute is a major biomedical research institution affiliated with both MIT and Harvard that conducts large-scale genomic and disease research. While broader in scope than HSCI, it shares faculty with Harvard and overlapping stem cell and regenerative biology research programs.

Regional players

  • Wellcome Sanger Institute: The Wellcome Sanger Institute is a leading UK-based genomic and cellular research institute with significant stem cell biology and organoid research programs (e.g., Human Cell Atlas). It is comparable to HSCI in terms of scientific scope but operates in a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Harvard Stem Cell Institute social profiles

Digital presence

Harvard Stem Cell Institute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Harvard Stem Cell Institute leadership team

Management profile

Number of profiles

Profiles6 records

Harvard Stem Cell Institute funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Harvard Stem Cell Institute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Harvard Stem Cell Institute

What does Harvard Stem Cell Institute do?

Harvard Stem Cell Institute operates as a University-wide research initiative that conducts stem cell and regenerative biology research, provides shared core facilities (iPS derivation, gene editing, bioinformatics), funds early-stage research through seed and capstone grants, supports faculty startup formation, and runs training programs including internships and fellowships. Its primary mission is to translate stem cell discoveries into clinical treatments for diseases including diabetes, cancer, cardiovascular disease, and neurodegenerative conditions.

Is Harvard Stem Cell Institute a public or private company?

Harvard Stem Cell Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Harvard Stem Cell Institute founded?

Harvard Stem Cell Institute was founded in 2004. It employs 51 to 100 people.

Where is Harvard Stem Cell Institute based?

Harvard Stem Cell Institute is headquartered in Cambridge, United States, in the North America region.

How does Harvard Stem Cell Institute make money?

Three revenue lines are on record. Philanthropic Gifts and Grants are the primary driver. The others are technology Licensing and Startup Revenue and fee-for-Service Core Facilities.

Who are Harvard Stem Cell Institute's main competitors?

Direct peers on record are Stanford Institute for Stem Cell Biology and Regenerative Medicine, Whitehead Institute for Biomedical Research, Buck Institute for Research on Aging, Allen Institute for Cell Science, Gladstone Institutes, Cincinnati Children's Center for Stem Cell and Organoid Medicine and New York Stem Cell Foundation (NYSCF). Broad incumbents are Scripps Research Institute and Broad Institute of MIT and Harvard. Wellcome Sanger Institute is listed as a regional player.

Does Harvard Stem Cell Institute have an API?

No public API is recorded for Harvard Stem Cell Institute.

What industry is Harvard Stem Cell Institute in?

Harvard Stem Cell Institute's product category is Biomedical Research - Stem Cell and Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Harvard GazetteHarvard Stem Cell Institute (HSCI)The Harvard Stem Cell Institute (HSCI) has published a comprehensive list of biotechnology companies founded or co-founded by its faculty members, highlighting the institute's significant role in commercializing stem cell and gene therapy research. The article details the specific scientific focus areas of these entities, ranging from CRISPR-based treatments and mRNA platforms to tissue engineering and rare disease therapies. This compilation serves as an overview of the academic-industry partnerships driving innovation in regenerative medicine and genetic disorders.PR NewswirePROF. DOUGLAS A. MELTON, WINNER OF THE III EDITION OF THE 'ABARCA PRIZE' FOR HIS DISRUPTIVE CURE OF TYPE 1 DIABETES, IS RECEIVED BY HIS MAJESTY THE KING OF SPAINProfessor Douglas A. Melton was received by His Majesty the King of Spain after being awarded the third edition of the Abarca Prize (Doctor Juan Abarca International Award for Medical Science) for his pioneering work developing a functional cure for type 1 diabetes through transplants of insulin-producing pancreatic beta cells. Melton, co-director of the Harvard Stem Cell Institute and distinguished research fellow at Vertex Pharmaceuticals, received 100,000 euros and a diploma for this breakthrough, which demonstrated successful clinical trial results achieving a 'functional cure' in type 1 diabetes patients. He indicated that his team is collaborating with various pharmaceutical companies to advance cell therapy treatments, with plans to expand clinical trials for this therapeutic approach.Harvard GazetteInvestigating the Role of Stem Cells in Tooth RepairDr. Yingzi Yang and Dr. Jennifer Gibbs received a $200,000 seed grant from the Harvard Stem Cell Institute to investigate how stem cells and sensory neurons contribute to dentin repair and pulp regeneration. The research aims to identify signaling pathways that enhance protective dentin formation to provide biological solutions for dental pain caused by deep cavities. This study seeks to bridge clinical and basic science expertise to develop novel therapeutic targets for treating dental inflammation and optimizing tooth retention.Harvard GazetteA promising cell therapy for obesity and diabetesHarvard Stem Cell Institute researchers led by Yu-Hua Tseng at Joslin Diabetes Center published a proof-of-concept study in Science Translational Medicine showing that CRISPR-engineered human white fat cells, modified to express the UCP1 gene, can treat obesity and metabolic syndrome in mice. Transplanted cells improved insulin sensitivity, glucose clearance and weight gain, largely by secreting nitric oxide that activated the mice's existing brown fat. The team is pursuing encapsulated or gene therapy routes for clinical use.News-MedicalResearch suggests new strategies for developing psoriasis therapiesResearchers from Brigham and Women's Hospital and Harvard Stem Cell Institute identified a loss of 5-hmC in the epigenome of psoriasis skin cells, which may drive skin thickening. They found preliminary data that vitamin C can restore 5-hmC levels, suggesting a potential therapeutic approach. Further research is needed to develop effective treatments.News-MedicalResearchers develop powerful new approach to improve maturation of miniature kidneysResearchers at Harvard's Wyss Institute exposed stem cell-derived kidney organoids to fluidic shear stress, significantly expanding vascular networks and improving maturation. The method enables better modeling of kidney diseases and drug toxicity testing, and may pave the way to vascularize other organoids like liver.PR NewswireLe Qatar Biomedical Research Institute de l'université Hamad Bin Khalifa forme un nouveau partenariat avec le Harvard Stem Cell InstituteQatar Biomedical Research Institute (QBRI) at Hamad Bin Khalifa University has signed a five-year collaborative research and training agreement with the Harvard Stem Cell Institute (HSCI) in the United States. The partnership aims to advance stem cell biology research and develop viable treatments for diabetes by producing insulin-producing cells for both Type 1 and Type 2 patients. Clinical trials arising from this research will be conducted in collaboration with Hamad Medical Corporation and Sidra Medicine in Qatar.PR NewswireDas Qatar Biomedical Research Institute der der Hamad Bin Khalifa University geht neue Partnerschaft mit dem Harvard Stem Cell Institute einDas Qatar Biomedical Research Institute (QBRI) der Hamad Bin Khalifa University in Katar hat eine fünfjährige Vereinbarung über gemeinsame Forschung und Lehre mit dem Harvard Stem Cell Institute (HSCI) in Boston unterzeichnet. Die Initiative umfasst Fachausbildung und Forschung im Bereich der Stammzellbiologie mit dem Ziel, das erste Zelltherapieprogramm der Region zur Behandlung von Diabetes zu entwickeln. Klinische Studien, die aus dieser Zusammenarbeit entstehen, sollen in Zusammenarbeit mit der Hamad Medical Corporation und dem Sidra-Medicine-Krankenhaus in Katar durchgeführt werden.PR NewswireQatar Biomedical Research Institute forma una nueva asociación con Harvard Stem Cell InstituteQBRI and HSCI have established a 5-year research and training collaboration focused on stem cell biology to advance diabetes treatment, marking Qatar's first regional cellular therapy program. Scientists from both institutions will share knowledge and best practices to accelerate discoveries into clinical applications. Clinical trials emerging from this partnership will be conducted with Hamad Medical Corporation and Sidra Medicine in Qatar.PR NewswireHamad Bin Khalifa University's Qatar Biomedical Research Institute Forms New Partnership With Harvard Stem Cell InstituteQatar Biomedical Research Institute signed a five-year research and training agreement with Harvard Stem Cell Institute to advance stem cell biology for diabetes treatment. The initiative aims to develop the region's first cell-therapy program, with clinical trials involving Hamad Medical Corporation and Sidra Medicine.